FY2026 Earnings Forecast for CRL Issued By Zacks Research

Charles River Laboratories International, Inc. (NYSE:CRL) – Investment analysts at Zacks Research lifted their FY2026 EPS estimates for shares of Charles River Laboratories International in a report issued on Monday, October 5th. Zacks Research analyst Team now anticipates that the medical research company will post earnings of $11.17 per share for the year, up from their previous estimate of $11.15. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $11.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q3 2027 earnings at $3.31 EPS, FY2027 earnings at $12.54 EPS, Q1 2028 earnings at $3.24 EPS, Q2 2028 earnings at $3.40 EPS, Q3 2028 earnings at $3.51 EPS and FY2028 earnings at $13.92 EPS.

A number of other research firms also recently issued reports on CRL. UBS Group began coverage on Charles River Laboratories International in a report on Wednesday, September 30th. They set a “buy” rating and a $357.00 price objective for the company. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday, July 1st. Morgan Stanley upped their price target on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Barclays raised their price target on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the stock an “overweight” rating in a research note on Friday, September 25th. Finally, Robert W. Baird lifted their price objective on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a report on Friday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $300.11.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $305.95 on Tuesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The firm has a market cap of $14.61 billion, a price-to-earnings ratio of -63.08, a price-to-earnings-growth ratio of 2.91 and a beta of 1.40. The stock’s 50-day moving average is $280.49 and its 200-day moving average is $220.15. Charles River Laboratories International has a one year low of $146.20 and a one year high of $333.30.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same period in the prior year, the business earned $3.12 EPS. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the transaction, the chief executive officer owned 36,013 shares of the company’s stock, valued at $10,080,038.70. The trade was a 15.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 33,561 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the sale, the director owned 31,596 shares in the company, valued at approximately $9,478,800. This represents a 51.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 90,990 shares of company stock valued at $25,731,388 in the last ninety days. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently made changes to their positions in CRL. Continuum Advisory LLC bought a new stake in Charles River Laboratories International during the second quarter worth $30,000. SHP Wealth Management bought a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $85,000. Hilltop National Bank increased its stake in shares of Charles River Laboratories International by 28.7% during the 2nd quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock worth $129,000 after purchasing an additional 127 shares during the last quarter. Trust Asset Management LLC acquired a new position in shares of Charles River Laboratories International during the 2nd quarter worth about $129,000. Finally, ABS Direct Equity Fund LLC bought a new stake in shares of Charles River Laboratories International in the 1st quarter valued at about $172,000. 98.91% of the stock is owned by institutional investors.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: New laboratory-technology partnership: Charles River and Autolomous announced a collaboration to improve laboratory execution systems. Their Apollo Orchestrate solution is designed to coordinate digital laboratory workflows within Charles River’s Apollo platform, potentially strengthening the company’s technology offering and creating longer-term growth opportunities. Charles River and Autolomous Partner to Transform Laboratory Execution Systems
• Positive Sentiment: Analysts modestly raised earnings forecasts: Zacks Research increased its FY2026 EPS estimate to $11.17 from $11.15, FY2027 to $12.54 from $12.49, and FY2028 to $13.92 from $13.82. Quarterly estimates for 2027 and 2028 were also raised slightly. The revisions indicate incremental confidence in Charles River’s earnings outlook, although the changes are relatively small and remain below the broader current-year consensus of $11.42. Research Analysts Offer Predictions for CRL FY2026 Earnings
• Neutral Sentiment: Recent momentum may be prompting consolidation: CRL recently gained 5.6% in a broad market rally and reached a new 52-week high. With the stock trading well above its 50-day and 200-day moving averages, investors may be locking in gains following the sharp advance. Charles River Laboratories International Jumps 5.6% in Broad Rally
• Negative Sentiment: Valuation and earnings risks remain: The stock’s rally has increased valuation sensitivity, while the company’s latest reported revenue declined 2.7% year over year and its net margin was negative. These factors could encourage profit-taking even as analysts maintain a generally positive earnings trajectory.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.